【建银国际：降百济神州目标价至140港元 料次季度业绩稳定】金十数据7月23日讯，建银国际发表报告，预计百济神州(06160.HK)次季度业绩稳定，GAAP净亏损将由首季2.51亿美元收窄至1.87亿美元。由于其BTK药物(Brukinsa)正将血癌相关适应症的覆盖范围扩大至更多海外国家，该行预测Brukinsa于第二季的销售额将按年增加88%或按季增加19%至5.79亿美元。与此同时，公司PD-1生物药(Tyvyt)预计将继续依赖在中国的销售额。建银国际指，由于主要药物的销售有望上升，估计百济神州第二季总收入为8.52亿美元，按年增加43%或按季增加13%。H股目标价由148港元下调至140港元。维持“跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.